Trials / Conditions / Myotonic Dystrophy Type 1 (DM1)

Myotonic Dystrophy Type 1 (DM1)

17 registered clinical trials studyying Myotonic Dystrophy Type 1 (DM1) — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy NCT07486934	Dyne Therapeutics	Phase 3
Enrolling By Invitation	A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I NCT06926621	Vertex Pharmaceuticals Incorporated	Phase 2
Recruiting	Music Intervention for Brain-Heart Disease in Myotonic Dystrophy Type 1 (DM1) NCT06809049	Hanns Lochmuller	N/A
Recruiting	Personalized Training for People With Rare Neuromuscular Disorders NCT06708468	Oslo University Hospital	N/A
Active Not Recruiting	Global Study of Del-desiran for the Treatment of DM1 NCT06411288	Avidity Biosciences, Inc.	Phase 3
Recruiting	A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) NCT06185764	Vertex Pharmaceuticals Incorporated	Phase 1 / Phase 2
Recruiting	Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With My NCT05481879	Dyne Therapeutics	Phase 1 / Phase 2
Recruiting	Remote Assessments and Genetic Determinants of Myotonic Dystrophy NCT07505342	University of Rochester	—
Completed	Technology Assisted Rehabilitation for Upper Limb Function in Myotonic Dystrophy Type 1 NCT05560438	University of Oslo	N/A
Completed	Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients NCT05027269	Avidity Biosciences, Inc.	Phase 1 / Phase 2
Active Not Recruiting	A Remote Physical Activity Program in the Population Suffering from Type 1 Myotonic Dystrophy NCT05072288	Université du Québec à Chicoutimi	N/A
Completed	Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders NCT04907162	LMU Klinikum	—
Completed	Breathlessness Assessment in Adult Patients With Myotonic Dystrophy Type 1 NCT04835298	CHU de Reims	—
Completed	Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1 NCT03959189	Expansion Therapeutics, Inc.	Phase 1
Completed	Brain Involvement in Myotonic Dystrophy Type I: From Functional Neuroimaging to the Impact on Quality of Life NCT03589677	IRCCS San Camillo, Venezia, Italy	—
Enrolling By Invitation	A Registered Observational Cohort Study of Myotonic Dystrophy Type 1 NCT06979024	First Affiliated Hospital of Fujian Medical University	—